Related Experiment Video
Updated: Jun 23, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of
Jensen Yeung1,2,3,4, Parbeer Grewal5,6, Mark Legault7
1Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada. jenseny@hotmail.com.
Introduction:
Treat-to-target (T2T) is a clinical paradigm intended to improve disease outcomes using measurement-based goals. Various groups of dermatologists have made T2T recommendations for managing moderate-to-severe atopic dermatitis (AD). These are based primarily on expert opinion, and their relevance for real-world outcomes has received limited attention. The objective of the present analysis was to assess the relevance of Canadian T2T criteria for moderate-to-severe AD in real-world practice by describing the agreement between achieving criteria and treatment decisions.
Methods:
Canadian dermatologists conducted retrospective chart reviews of adult patients with moderate-to-severe AD treated with an advanced systemic therapy (AST) in clinical practice. T2T criteria were applied to patient outcomes and treatment decisions were reported.
Results:
Charts were reviewed for 297 patients who were assessed a combined 503 times over up to 1 year of treatment. Treatment modifications were made in less than 10% (38/425, 9%) of cases where patients met target and more than half (41/78, 53%) where they missed target. For patients missing target, switching AST was the most common modification.
Conclusions:
Treatment decisions were generally aligned with the retrospectively applied Canadian T2T criteria. While these results require further validation, they suggest that the T2T criteria represent valid thresholds for clinical decision-making.
